:Dpa    (DrugBank: -)

4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症1
6パーキンソン病3
13多発性硬化症/視神経脊髄炎5
85特発性間質性肺炎1

2. 筋萎縮性側索硬化症 [臨床試験数:508,薬物数:530(DrugBank:146),標的遺伝子数:170,標的パスウェイ数:221
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 508 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02405403March 20152/3/2015Microglial Activation Role In ALS (MARIA)Microglial Activation Role In ALS (MARIA)Amyotrophic Lateral SclerosisDrug: [18F]DPA-714 PETUniversity Hospital, ToursNULLWithdrawn18 YearsN/AAll0Early Phase 1France

6. パーキンソン病 [臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 2,123 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03230526April 20, 201818/7/2017Identification of a Biomarker Predictive of Evolution of Parkinson DiseaseBrain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?Parkinson DiseaseDrug: [18F]DPA-714 PET scanNantes University HospitalNULLRecruiting40 Years67 YearsAll64Phase 2France
2NCT03457493March 22, 201823/2/2018TSPO-PET for Neuroinflammation in Parkinson's DiseaseUAB Neuroinflammation in Parkinson's Disease - TSPO-PET SubstudyParkinson DiseaseDrug: DPA-714-PET/MRIUniversity of Alabama at BirminghamNULLRecruiting30 YearsN/AAll20Phase 1/Phase 2United States
3NCT02319382June 201218/11/2014Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PETHigh Resolution PET Imaging of Microglial Activation in Parkinson's Disease (PD) With a New Tracer [18F]DPA-714Parkinson's Disease With LRRK2 Mutation;Healthy Controls;Parkinson's Disease Without LRRK2 MutationRadiation: PET with the tracer 18F-DPA-714;Radiation: PET with the tracer 11C-PE2I;Other: MRIAssistance Publique - Hôpitaux de ParisFrance Parkinson AssociationRecruiting18 YearsN/ABoth46N/AFrance

13. 多発性硬化症/視神経脊髄炎 [臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228
Searched query = "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 3,050 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03759522February 3, 20196/11/2018Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;HealthyDrug: DPA-714 PET/MRIUniversity of Alabama at BirminghamNULLRecruiting18 Years65 YearsAll120Phase 1United States
2NCT03691077November 11, 201828/9/2018Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714A Prospective Study Evaluating the Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in Multiple Sclerosis Using PET-MRI With 18F-DPA714Multiple Sclerosis;Relapse;Primary Progressive Multiple SclerosisDrug: OcrelizumabAssistance Publique - Hôpitaux de ParisRoche Pharma AG;Institut du Cerveau et de la Moelle épinièreRecruiting18 Years60 YearsAll51Phase 3France
3EUCTR2017-004158-40-FR11/09/201804/07/2018NAA Prospective study evaluating the effect of ocrelizumab on brain innate immune Microglial cells Activation in Multiple Sclerosis using PET-MRI with 18F-DPA714 - INN-MS Patients with Relapsing MS or primary progressive MS
MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
71 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): no Therapeut1c conf1rmatory - (Phase 3): yes Therapeut1c use (Phase 4): noFrance
4EUCTR2014-002547-17-NL18/12/201401/12/2014Imaging of inflammation in the cortex of the brain in progressive MS patientsGrey matter microglial imaging with [18F]DPA-714 in progressive MS patients - [18F]DPA-714 PET in MS Progressive multiple sclerosis, both primary and secondary progressive
MedDRA version: 17.1Level: PTClassification code 10063401Term: Primary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.1Level: PTClassification code 10053395Term: Progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: [18F]DPA-714
INN or Proposed INN: [18F]DPA-714
Other descriptive name: [18F]DPA-714
VU University Medical CenterNULLNot RecruitingFemale: yes
Male: yes
Netherlands
5NCT02305264February 201225/1/2013Imaging of Intracerebral Inflammation in MSImaging of Intracerebral Inflammation in the Progressive Phase of Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary ProgressiveDrug: 18F-DPA-714 and 18F-FDGAssistance Publique - Hôpitaux de ParisNULLRecruiting18 Years65 YearsAll65N/AFrance

85. 特発性間質性肺炎 [臨床試験数:514,薬物数:377(DrugBank:108),標的遺伝子数:97,標的パスウェイ数:204
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 514 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04362644December 1, 20202/3/2020Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary FibrosisMolecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714University of Alabama at BirminghamNULLNot yet recruiting40 Years85 YearsAll10Phase 1United States